Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23990580 | 0.88 | JAK3 (0.41) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL14778518 | 0.85 | CTSK (0.53) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL3212854 | 0.85 | CTSK (0.53) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL3212857 | 0.85 | CTSK (0.53) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL14780294 | 0.83 | CTSK (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1536324 | 0.81 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL5142562 | 0.81 | CTSK (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL15510764 | 0.81 | CTSK (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1486237 | 0.81 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL12570837 | 0.81 | CTSK (0.45) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772277-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20130072467-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072467-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | ESRRA, ESRRB, ESR2 | CTSK 4764/4885CTSS 4792/4885CA1 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.